Nonalcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease worldwide, with a global prevalence of approximately 25%. NAFLD prevalence is even higher in patients with type 2 diabetes, reaching about 55%, and up to 90% in obese individuals with a body mass index above 40 kg/m2. NAFLD is characterized by the accumulation of lipids in the liver, particularly in the absence of high‑risk alcohol consumption, and is usually a diagnosis of exclusion. It is often associated with type 2 diabetes, as insulin resistance (IR) and hyperinsulinemia are known to be favoring factors. However, recent studies have reported a growing incidence of NAFLD also in type 1 diabetes (T1DM). The increasing prevalence of metabolic syndrome in these patients seems to explain, at least in part, this phenomenon. Nevertheless, other mechanisms, such as oxidative stress, poor glucose control, and long‑lasting hyperglycemia, but also exogenous insulin administration, may play an important role in T1DM‑associated NAFLD.